The Food and Drug Administration has approved Katerzia (Azurity Pharmaceuticals), a ready-to-use, oral suspension formulation of amlodipine.
Katerzia is indicated for the treatment of hypertension in adults and pediatric patients ≥6 years of age; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and to reduce the risk of hospitalization for angina and the risk of coronary revascularization procedure in patients with recently documented coronary artery disease without heart failure or an ejection fraction <40%.
Katerzia is available as a 1mg/mL (equivalent to 1.30mg of amlodipine benzoate) liquid suspension and is supplied as 150mL in a 185mL bottle.
“The addition of Katerzia complements our existing pediatric hypertension portfolio and will strengthen the overall offering from Azurity,” said Neal Muni, MD, MSPH, President and Chief Executive Officer of Azurity Pharmaceuticals. Azurity also manufacturers oral solution formulations of enalapril (Epaned), lisinopril (Qbrelis), methotrexate (Xatmep), and vancomycin (Firvanq).
For more information visit azurity.com.
This article originally appeared on MPR